This is an abridged prospectus containing salient features of the Red Herring Prospectus (the "RHP"). You are encouraged to read greater details available in the RHP www.krmayurvedaindia.com

THIS ABRIDGED PROSPECTUS CONSISTS OF SEVEN (7) PAGES. PLEASE ENSURE THAT YOU HAVE RECEIVED ALL THE PAGES.

Please scan this QR code to view the RHP

KRM AYURVEDA LIMITED

(Formerly known as KRM Ayurveda Private Limited)

CIN: U24239DL2019PLC354658

REGISTERED OFFICE	CORPORATE OFFICE	CONTACT PERSON	EMAIL & TELEPHONE	WEBSITE
A-16 G T Karnal road Industrial Area, North West, Delhi, Delhi, India-110033.	N.A.	Ms. Pooja Garg Company Secretary & Compliance Officer	compliance@krmayurveda.com & +91- 9289101700	www.krmayurvedaindia.com

NAME OF PROMOTER(S) OF THE COMPANY

MR. PUNEET DHAWAN AND MRS. TANYA DHAWAN

DETAILS OF OFFER TO PUBLIC, PROMOTERS/ SELLING SHAREHOLDERS

Type of Issue (Fresh/ OFS/ Fresh & OFS)	Fresh Issue Size (by no. of shares or by amount in Rs)	OFS Size (by no. of shares)	Total Issue Size (by no. of shares or by amount in Rs)	Issue Under 229(2)	Share Reservation		
					QIB including Anchor	NII	Individual Investor
Fresh Issue	Upto 57,40,000 Equity Shares of Face Value of Rs. 10/- each aggregating up to Rs. [●] lakhs	NIL	Upto 57,40,000 Equity Shares of Face Value of Rs. 10/- each aggregating up to Rs. [●] lakhs	The Offer is being made pursuant to Regulation 229(2) of SEBI (ICDR) Regulations.	Not more than 25,74,000 Equity Shares	Not more than 7,80,000 Equity Shares	Not more than 18,12,000 Equity Shares

These equity shares are proposed to be listed on Emerge Platform NSE Limited.

OFS: Offer for Sale- NA

Price Band, Minimum Bid Lot & Indicative Timelines	
Price Band*	Rs. 128/- per Equity Shares to Rs. 135/- per Equity Shares
Minimum Bid Lot Size	2,000 Equity Shares
Bid/Offer Open On	January 21, 2026
Bid/Offer Closes On	January 23, 2026
Finalisation of Basis of Allotment	On or before January 27, 2026
Initiation of Refunds	On or before January 28, 2026
Credit of Equity Shares to Demat accounts of Allottees	On or before January 28, 2026
Commencement of trading of Equity Shares	On or before January 29, 2026

*For details of price band and basis of offer price, please refer to pre-issue advertisement and Red Herring Prospectus (RHP).

Details of WACA of all shares transacted over the trailing twelve months from the date of RHP:

Period	Name of Promoters/ Selling Shareholders	Weighted Average Cost of Acquisition (in Rs.)	Upper End of the Price Band is 135 "X" times the WACA	Range of acquisition price Lowest Price 128 - Highest Price 135 (in Rs.)
Trailing Twelve Month from the date of RHP	Mr. Puneet Dhawan	Nil	Nil	Lowest Price:0, Highest Price: 0
	Mrs. Tanya Dhawan	Nil	Nil	Lowest Price:0, Highest Price: 0

WACA: Weighted Average Cost of Acquisition shall be calculated on fully diluted basis for the trailing twelve months from the date of RHP.

This being the first public issue of our Company, there has been no formal market for the Equity Shares. The face value of our Equity Shares is ₹ 10 each and the Floor Price and Cap Price are 12.80 times and 13.50 times of the face value of the Equity Shares, respectively. The Floor Price, Cap Price and Issue Price (determined and justified by our Company in consultation with the Book Running Lead Manager as stated in "Basis for Issue Price" on page 132- of this Red Herring Prospectus) should not be taken to be indicative of the market price of the Equity Shares after the Equity Shares are listed. No assurance can be given regarding an active or sustained trading in the Equity Shares or regarding the price at which the Equity Shares will be traded after listing.

GENERAL RISKS

Investments in Equity and Equity related securities involve a degree of risk and investors should not invest any funds in this issue unless they can afford to take the risk of losing their entire investment. Investors are advised to read the risk factors carefully before taking an investment decision in the Issue. For taking an investment decision, investors must rely on their own examination of our Company and the Issue including the risks involved. The Equity Shares issued in the Issue have not been recommended or approved by the Securities and Exchange Board of India ("SEBI"), nor does SEBI guarantee

the accuracy or adequacy of the Red Herring Prospectus. Specific attention of the investors is invited to the section "Risk Factors" beginning on page 29 of this Red Herring Prospectus and on 6 of this Abridged Prospectus
PROCEDURE
You may obtain a physical copy of the Bid-cum-Application Form and the RHP from the stock exchange, syndicate members, registrar to the issue, share transfer agents, depository participants, stockbrokers, underwriters, bankers to the issue, investors' associations or Self Certified Syndicate Banks.
If you wish to know about processes and procedures applicable to this issue, you may request for a copy of the RHP and/or the General Information Document (GID) from the BRLM's or download it from the websites of the Stock Exchange i.e. https://www.nseindia.com/ and the BRLMs i.e., www.nexgenfin.com.

PRICE INFORMATION OF BOOK RUNNING LEAD MANAGERS

NEXGEN Financial Solutions Pvt. Ltd.

S. No.	Issuer Name	Issue Size (Rs. in Cr.)	Issue Price (Rs.)	Listing Date	Opening Price on Listing Date	+/-% change in closing price, [+/-% change in closing benchmark]- 30th calendar days from listing	+/-% change in closing price, [+/-% change in closing benchmark]- 90th calendar days from listing	+/-% change in closing price, [+/-% change in closing benchmark]- 180th calendar days from listing
Initial Public Offering - Main Board								
N.A.								
Initial Public Offering – SME Exchange								
N.A.								

* Disclosures subject to recent 7 issues (Initial Public offerings) in current financial year and two preceding financial years managed by each Merchant Banker with common issues disclosed once.

Name of BRLMs and contact details (telephone and email id) of each BRLM	**NEXGEN Financial Solutions Pvt. Ltd.** **Address: 709, Madhuban Building, 55, Nehru Place, New Delhi – 110019** **Tel**.: 91 11 41407600; | **Email**: ipo@nexgenfin.com | **Website**: www.nexgenfin.com **Contact Person:** Mr. Shubham Gupta **SEBI Registration No**.: INM000011682
Name of Syndicate Members	NA

Name of the Market Maker(s) and contact details (telephone and email id) of each Market Maker	**Mansi Share and Stock Broking Private Limited** Address: B-201, Avirahi Building Behind Adidas Showroom, S.V. Road Borivali (West) Mumbai-400092 Tel No.: 02240503870 Email Id: compliance@mansishares.in Contact Person: Mr. Deep Paresh Shah SEBI Registration No.: INZ000247433 **Nikunj Stock Brokers Limited** Address: A-92, G.F Left Portion, Kamla Nagar, New Delhi 110007, India Tel No.: 011-47030017-18/9811322534 Email Id: complianceofficer@nikujonline.com Contact Person: Mr. Pramod Kumar Sultania SEBI Registration No.: INZ000169335 Website: www.nikunjonline.com
Name of Registrar to the Issue and contact details (telephone and email id)	**SKYLINE FINANCIAL SERVICES PRIVATE LIMITED** **Address**: D-153A, 1st Floor, Okhla Industrial Area Phase-I, New Delhi – 110020, India **Telephone**: 011-40450193-97 **Email**: ipo@skylinerta.com, grievances@skylinerta.com **Website**: www.skylinerta.com **Contact Person**: Mr. Anuj Rana **SEBI Registration Number**: INR000003241 **CIN**: U74899DL1995PTC071324
Name of Statutory Auditor	**M/s Shiv & Associates.** **Address:** Shop no. 67, First Floor, Sector-10 Market, Faridabad, 121006. **Tel No.:** + 0129-4887247 **Email Id**: abhishek@cashiv.in **Contact Person:** CA Abhishek Vashisht **Peer Review Certificate No.:** 017665
Name of Credit Rating Agency and the rating or grading obtained, if any	Not Applicable
Name of Debenture trustee, if any.	Not applicable
Self-Certified Syndicate Banks	The lists of banks that have been notified by SEBI to act as SCSB for the Applications Supported by Blocked Amount (ASBA) Process are provided on the website of SEBI. For details on Designated Branches of SCSBs collecting the Bid Cum Application Forms, please refer to the below mentioned SEBI link https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognised=yes
Non-Syndicate Registered Brokers	You can submit Application Forms in the Issue to Non-Syndicate Registered Brokers at the Non-

	Syndicate Broker Centers. For further details, see section titled "Issue Procedure" beginning at page no. 371 of the Red Herring Prospectus
Details regarding website address(es)/ link(s) from which the investor can obtain list of registrar to issue and share transfer agents, depository participants and stock brokers who can accept application from investor (as applicable)	The details of the Designated Registrar and Share Transfer Agents Locations and Designated Collecting Depository Participant Locations, along with their names and contact details are available on the website of the Emerge platform of NSE Limited (NSE Emerge) (https://www.nseindia.com/) and updated from time to time.

PROMOTERS OF THE ISSUER COMPANY			
S.No.	**Name**	**Individual/ Corporate**	**Experience & Educational Qualification**
1.	Mr. Puneet Dhawan	Individual	Mr. Puneet Dhawan, aged 37, is one of promoters. He was appointed as Managing Director on March 15, 2025 of our company for the term of 5 years. He commenced his professional journey in the field of Ayurveda in the year 2013, upon obtaining his Bachelor of Ayurvedic Medicine and Surgery (BAMS) degree from the University of Delhi. Following the completion of his degree, he established his clinical practice under the name "Karma Ayurveda" in Delhi in 2013. With the vision to expand and formalize his business operations, he subsequently promoted and incorporated KRM Ayurveda Private Limited in the year 2019. He has been consistently engaged in the practice of Ayurveda since 2013, contributing to the growth and advancement of the organization under his leadership. Mr. Puneet Dhawan, with his strong educational background and extensive industry knowledge, serves as a valuable leader within the Company. Recognized at the Indian Healthcare Federation (IFA) with the award for Best Ayurveda Doctor in India, Dr. Puneet Dhawan has significantly contributed to the growth and reputation of the hospitals by emphasizing excellence in patient care and quality healthcare delivery.
2.	Mrs. Tanya Dhawan	Individual	Mrs. Tanya Dhawan, aged 34 years, is one of our promoters and serves as Non-Executive Director of the company. She has been associated with the Company since its incorporation in 2019 as a Promoter and Director. During her initial tenure of two years on the Board, she was actively involved in shaping the Company's strategic direction and ensuring effective governance. After obtaining a professional diploma in Dietetics, she pursued a career in health consultancy, further enhancing her expertise in nutrition and wellness. She rejoined the Board of the Company in September 2025 as a Non-Executive Director. She continues to contribute to the Company through her professional services in the areas of marketing and dietetic consultancy. She also holds the degree of master's in mass communication in 2014 from Guru Gobind Singh Indraprastha University. Mrs. Dhawan's ability to combine her knowledge of communication and health has allowed her to craft effective wellness campaigns for individuals, helping them lead healthier, more balanced lives.

For details about the "Our Promoter", "Our Promoter Group", please refer to Page No**.** 300 and 305 respectively of the Red Herring Prospectus.

BUSINESS OVERVIEW AND STRATEGY	
Company Overview:	Our Company was incorporated as a Private Limited Company under the name of "KRM Ayurveda Private Limited" under the Companies Act, 2013 vide certificate of incorporation dated September 03, 2019, issued by Registrar of Companies, Delhi, bearing CIN U24239DL2019PTC354658. Further, our Company was converted into a Public Limited Company in pursuance of a special resolution passed by the members of our Company at the Extra Ordinary General Meeting held on November 23, 2024 and the name of our Company was changed from "KRM Ayurveda Private Limited" to "KRM Ayurveda Limited" & Registrar of Companies, CPC has issued a new certificate of incorporation consequent upon conversion dated December 24, 2024 bearing CIN U24239DL2019PLC354658. For further details of incorporation please refer to section titled "Our History and Certain Other Corporate Matters" beginning on page 273 of this Draft Red Herring Prospectus.
Business Overview:	Our Company, established in 2019, is operating a network of hospitals and clinics across multiple cities in India as well as marked its presence in abroad through telemedicines consulting and sales. Presently, Company runs 6 (Six) Hospitals and 5 (Five) Clinics at different locations in the country. Though KRM Ayurveda started off as a kidney hospital and it continues to provide specialized treatment for kidney disorders, the Company has widened its horizons in the past few years and has now evolved for various health disorders such as kidney disorder, Liver Cirrhosis, Diabetes, Fatty Liver, Arthritis etc. Company has marked its reach globally as well through Tele-Consultancy Services. Further, we focus on specialized segments within the medical and healthcare domain that address specific health issues and challenges, such as addiction, personal care, wellness, and related areas and for that we are engaged into trading of Ayurvedic medicine, oils and supplements.
Product/Service Offering: Revenue Segmentation by Product/Service Offering	We have two Service Offerings 1. Hospitals 2. Clinics 3. Teleconsultation Services 4. KRM Ayurveda Products
Geographies Served:	For details regarding "Geographical wise revenue break up", please refer to chapter titled "Our Business" on Page no. 191 of the Red Herring Prospectus.

Revenue Segmentation by Geographies	
Key Performance Indicators:	For details regarding "Key Performance Indicators" refer to Chapter – "Basis for Issue Price" on Page no. 132 of the Red Herring Prospectus.
Client Profile or Industries Served: Revenue Segmentation in terms of top 5/10 Client or Industries	For details regarding "Our Client Profiles and Revenue Segmentation" refer to Chapter – "Our Business" on Page no. 191 respectively of the Red Herring Prospectus.
Intellectual Property, if any:	As on the date of Red Herring Prospectus, we have Two Intellectual property rights registered in our name. For details refer to Chapter – "Our Business" on Page no. 191 of the Red Herring Prospectus.
Market Share:	Not ascertainable
Manufacturing Plant, if any:	NA
Employee Strength:	As on December 31, 2025, we have the total strength of 443 employees on payroll basis. For details see "Our Business" on page 191 of the Red Herring Prospectus.

Note: (1) The quantitative statements shall be substantiated with Key Performance Indicators (KPIs) and other quantitative factors.
(2) No qualitative statements shall be made which cannot be substantiated with KPIs.
(3) Information provided in the table should not exceed 1000 words.

BOARD OF DIRECTORS				
S. No.	**Name**	**Designation**	**Experience & Educational Qualification**	**Other Directorships**
1.	Mr. Puneet Dhawan	Managing Director	**Experience**: He has more than 12 Years in Ayurveda industry. **Educational Qualification**: Bachelor of Ayurvedic Medicine & Surgery (BAMS).	**Indian Private Companies** Nil **Indian Public Companies** Nil **Section 8 Companies** Nil **Indian LLPs** Nil **Partnership Firm** Nil **Foreign Companies** Nil
2.	Mrs. Tanya Dhawan	Director	**Experience:** She has around 3 years of experience in Ayurveda industry. **Educational Qualification:** Master of Mass Communication	**Indian Private Companies** Nil **Indian Public Companies** Nil **Section 8 Companies** Nil **Indian LLPs** Nil **Partnership Firm** Nil **Foreign Companies** Nil
3.	Mr. Sanchit Hans	Whole Time Director	**Experienc**e: He has over 4 years of experience in Business Administration **Educational Qualification:** Bachelor of Commerce (B. Com)	**Indian Private Companies** Nil **Indian Public Companies** Nil **Section 8 Companies** Nil **Indian LLPs** Nil **Foreign Companies** Nil
4.	Ms. Vandana Gupta	Independent Director	**Experienc**e: She has over 21 Years in Compliance and corporate governance. **Educational Qualification: :** Company Secretary and LLB	Indian Private Companies 1. Himachal Energy Private Limited Indian Public Companies 1. Blue Horizons Investments Limited 2. Crazy Snacks Limited 3. KRA Leasing Limited 4. Skyline India Limited 5. Confidence petroleum India Limited Section 8 Companies Nil Indian LLP Nil Foreign Companies Nil
5.	Ms. Laxmi	Independent Director	**Experience:** She has over 3	**Indian Private Companies**

			Years in Sales and Marketing. **Educational Qualification:** Master of Commerce (M.Com)	1. Weare8 India Media Private Limited **Indian Public Companies** Nil **Section 8 Companies** Nil **Indian LLPs** Nil **Foreign Companies** Nil

For further details, please refer chapter titled "Our Management" on Page No. 278 of the Red Herring Prospectus.

OBJECTS OF THE ISSUE

DETAILS OF MEANS OF FINANCE.

The following table sets forth details of the Net Proceeds:

S. No	Particulars	Amount in Lakh
1	Gross Issue Proceeds	[●]*
2	Less: Issue Related Expenses	[●]**
	Net proceeds	[●]*

**Subject to finalization of basis of allotment.*
***As per the certificate given by M/s Shiv & Associates., Chartered Accountants, dated January 02, 2026, the Company has incurred Rs. 17.74 Lakhs towards issue expenses*

We propose to deploy the Net Proceeds for the previously mentioned purposes in accordance with the estimated schedule of implementation and deployment of funds set forth in the table below.

(Amount in Lakh)

S. N.	Particulars	Amount (In Rs. Lakh)
1.	Capital Expenditure for Construction and Development of Telemedicine Operational Facilities	1,366.68
2.	Purchase of CRM Software and Hardware Infrastructure	141.55
3.	Human Resources	543.82
4.	Repayment/Prepayment of loan	1,250.00
5.	Working Capital Requirement	2,290.00
6.	General Corporate Purposes*	[●]
	Net Proceeds	[●]

**To be finalised upon determination of the Issue Price and updated in the Prospectus prior to filing with the RoC and the amount to be utilized for general corporate purposes shall not exceed 15% of the amount raised by our Company or Rs. 10 Crores, whichever is lower.*

The objects detailed above are intended to be funded from the proceeds of the Issue while any remaining funding needs will be met through the company's internal accruals. Accordingly, we confirm that there is no requirement for us to make firm arrangements of finance through verifiable means towards at least 75% of the stated means of finance, excluding the amount to be raised from the proposed Issue.

Details and reasons for non -deployment or delay in deployment of proceeds or changes in utilization of issue proceeds of past public issues / rights issue, if any, of the Company in the preceding 10 years: Not Applicable

Name of monitoring agency, if any: Our Company has appointed a Monitoring Agency naming CARE Ratings Limited on a voluntary basis for monitoring the utilization of Gross Proceeds.

Terms of Issuance of Convertible Security, if any:

Convertible securities being offered by the Company	Not Applicable
Face Value / Issue Price per Convertible securities	
Issue Size	
Interest on Convertible Securities	
Conversion Period of Convertible Securities	
Conversion Price for Convertible Securities	
Conversion Date for Convertible Securities	
Details of Security created for CCD	

Shareholding Pattern:

Sr. No.	Particulars	Pre-Issue number of shares	% Holding of Pre issue
1.	Promoter and Promoter Group	1,43,03,500	92.16%
2.	Public	12,17,300	7.84%
	Total	**1,55,20,800**	**100.00%**

Shareholding Pattern: For more details, please refer to "Capital Structure" on page no. 86 of the RHP.

RESTATED FINANCIALS OF OUR COMPANY

On the basis of restated Standalone financial statements

(Amount in Lakhs)

Particulars	September 30,2025	March 31, 2025	March 31, 2024	March 31, 2023

Share Capital	1,552.08	15.00	15.00	15.00
Reserve & Surplus	2,060.73	2,372.58	1,162.85	821.63
Net Worth	3,612.81	2,387.58	1,177.85	836.63
Revenue from operation	4,835.71	7,655.27	6,715.57	8,928.71
Profit after Tax	813.92	1,209.72	341.22	759.80
Basic	5.24	8.06	2.27	5.07
Diluted	5.24	8.06	2.27	5.07
NAV per Equity Share (in Rs.)	25.64	1602.40	7,852.34	5,577.54
Total borrowings				
- Long Term	1,496.91	1,862.81	2,054.29	1,764.16
- Short Term	1,009.59	1,257.20	263.21	223.25

INTERNAL RISK FACTORS

The below mentioned risks are top 5 risk factors as per the RHP.

1. Our Registered Office and other hospital premises from where we operate are not owned by us. If we are required to vacate the same, due to any reason whatsoever, it may adversely affect our business operations.
2. Our Company has experienced, and may continue to experience, a higher rate of employee attrition in recent periods, including among frontline and technical staff.
3. Majority of our state wise revenues from operations for the last 3 years is majorly derived from our Top 2 States. Any adverse developments affecting our operations in this state could have an adverse impact on our revenue and results of operations.
4. Our business is working capital intensive, and fluctuations or inadequate financing of our working capital requirements may adversely affect our business, financial condition, and results of operations.
5. We are dependent on third-party transportation service providers for delivery of our raw materials and finished products. Any disruption in such transportation arrangements or increase in transportation costs may materially and adversely affect our business, financial condition, results of operations, and cash flows

For further details, please refer chapter titled "Risk Factors" on page no. 29 of the RHP.

SUMMARY OF OUTSTANDING LITIGATIONS, CLAIMS AND REGULATORY ACTION

A. Total Number of outstanding litigations involving our company and our promoter involved:

Name	Criminal Proceedings	Tax Proceedings	Civil Proceedings	Statutory or regulatory actions	Other Material litigations	Aggregate amount involved*
Company						
By	Nil	Nil	1	Pending for Adjudication	Nil	INR 10,77,264.59
Against	Nil	Nil	1	Pending for Adjudication	Nil	INR 50,50,000
Promoter						
By	Nil	Nil	1	Appeal Pending for Adjudication	Nil	INR 13,35,056
Against	Nil	Nil	2	Pending for Adjudication	Nil	INR 2,50,00,000
Director/KMP						
By	Nil	Nil	Nil	Nil	Nil	Nil
Against	Nil	Nil	Nil	Nil	Nil	Nil
Subsidiary						
By	Nil	Nil	Nil	Nil	Nil	Nil
Against	Nil	Nil	Nil	Nil	Nil	Nil
Group Companies						
By	Nil	Nil	Nil	Nil	Nil	Nil
Against	Nil	Nil	Nil	Nil	Nil	Nil
Total	Nil	Nil	5		Nil	INR 3,24,62,320.59

**To the extent quantifiable.*

For details of the said case refer chapter titled "Outstanding Litigations and material Developments" beginning on 332 this Red Herring Prospectus

B. Brief Details of top 5 Material outstanding litigation against the Company and Amount involved:

S. No.	Particulars	Litigation Filed by	Current Status	Amount Involved (Rs.)
1	Consumer Compliant under section 35 of the Act	Mr. V. K. Bansal	Pending	50,50,000/-

C. Regulatory Action, if any - disciplinary action taken by SEBI or stock exchanges against the Promoters in last 5 financial years including outstanding action, if any: None

D. Brief details of outstanding criminal proceedings against Promoters: **NA**

ANY OTHER INFORMATION AS PER LEAD MANAGER / ISSUER COMPANY – NIL

DECLARATION BY THE COMPANY

We, hereby declare that, all the relevant provisions of the Companies Act, 2013 and the guidelines/regulations issued by the Government of India or the guidelines/regulations issued by the Securities and Exchange Board of India, established under section 3 of the Securities Exchange Board of India Act, 1992, as the case may be, have been complied with no statement made in the Red Herring Prospectus is contrary to the provisions of Companies Act, 2013, the Securities and Exchange Board of India Act, 1992 or rules made there under or regulations/guidelines issued, as the case may be. We further certify that all the statements made in the Red Herring Prospectus are true and correct.